Bioverativ (Bioverativ) Total Assets : $1,618 Mil (As of Dec. 2017)

View and export this data going back to 2017. Start your Free Trial

What is Bioverativ Total Assets?

Bioverativ's Total Assets for the quarter that ended in Dec. 2017 was $1,618 Mil.

Total Assets is connected with ROA %. Bioverativ's annualized ROA % for the quarter that ended in Dec. 2017 was 36.80%. Total Assets is also linked to Revenue through Asset Turnover. Bioverativ's Asset Turnover for the quarter that ended in Dec. 2017 was 0.21.

Bioverativ Total Assets Historical Data

The historical data trend for Bioverativ's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioverativ Total Assets Chart

Bioverativ Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Total Assets

376.40

475.60

731.90

1,618.30

Bioverativ Quarterly Data
	Dec13	Dec14	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17
Total Assets	Get a 7-Day Free Trial							731.90	796.60	1,357.50	1,453.50	1,618.30

Bioverativ Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Bioverativ's Total Assets for the fiscal year that ended in Dec. 2017 is calculated as

Total Assets	=	Total Equity (A: Dec. 2017 )	+	Total Liabilities (A: Dec. 2017 )
	=	897.6	+	720.7
	=	1,618

Bioverativ's Total Assets for the quarter that ended in Dec. 2017 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2017 )	+	Total Liabilities (Q: Dec. 2017 )
	=	897.6	+	720.7
	=	1,618

Bioverativ (NAS:BIVV) Total Assets Explanation

Total Assets is connected with ROA %.

Bioverativ's annualized ROA % for the quarter that ended in Dec. 2017 is

ROA %	=	Net Income (Q: Dec. 2017 )	/	( (Total Assets (Q: Sep. 2017 )	+	Total Assets (Q: Dec. 2017 ))	/ count )
	=	565.2	/	( (1453.5	+	1618.3)	/ 2 )
	=	565.2	/	1535.9
	=	36.80 %

Note: The Net Income data used here is four times the quarterly (Dec. 2017) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Bioverativ's Asset Turnover for the quarter that ended in Dec. 2017 is

	Asset Turnover
=	Revenue (Q: Dec. 2017 )	/	( (Total Assets (Q: Sep. 2017 )	+	Total Assets (Q: Dec. 2017 ))	/ count )
=	328.7	/	( (1453.5	+	1618.3)	/ 2 )
=	328.7	/	1535.9
=	0.21

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Bioverativ Total Assets Related Terms

Thank you for viewing the detailed overview of Bioverativ's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioverativ (Bioverativ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioverativ Inc (NAS:BIVV) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.bioverativ.com

Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Brian S Posner	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Cox	director, officer: Chief Executive Officer	C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
John Greene	officer: EVP, CFO and Treasurer	51 LIME STREET, LONDON X0 EC3M 7DQ
Geno J Germano	director	5 GIRALDA FARMS, MADISON NJ 07940
Louis J Paglia	director	C/O UIL HOLDINGS CORP, 157 CHURCH STREET, NEW HAVEN CT 06506
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Diantha Duvall	officer: Chief Accounting Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Vivaldi Coelho Rogerio	officer: EVP, Chief Global Therapeutics	225 SECOND AVENUE, WALTHAM MA 02451
Harris Timothy J.r.	officer: EVP, R & D	C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451
Lucia Celona	officer: EVP, HR & Corp Commun. Officer	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Richard Brudnick	officer: EVP, Business Development	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142

Bioverativ (Bioverativ) Headlines

From GuruFocus

5 Companies Hit 52-Week Highs

By yifan900 yifan900 • 05-29-2018

Jeff Ubben Buys 1, Sells 1 in 1st Quarter

By Sydnee Gatewood Sydnee Gatewood • 05-24-2017

Seeking Value in Biotech: Bioverativ

By Mark Yu Mark Yu • 06-29-2017